Developer docs
API playgroundTry for free, no card

Search company profiles

AMR Centre

Full company profile

uuid0004kcc

Namestring
AMR Centre
Legal namestring
Infex Therapeutics Ltd.
Websiteurl
amrcentre.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Infex Therapeutics Ltd (also known as InfexTx, and previously associated with the AMR Centre brand founded in 2016) is a UK-based clinical-stage biopharmaceutical company headquartered at Alderley Park in the North West of England. The company acquires, develops, and licences innovative drugs targeting pandemic infections and antimicrobial-resistant pathogens, with a particular emphasis on first-in-class anti-virulence therapeutics — drugs designed to neutralise bacterial virulence factors rather than kill bacteria directly, in order to reduce selective pressure for resistance. Headcount is in the 11–50 range and the company is privately held.

The pipeline centres on two named candidates: RESP-X (INFEX702), a first-in-class anti-virulence antibody drug in development for non-cystic fibrosis bronchiectasis patients colonised with Pseudomonas aeruginosa, which reported positive Phase IIa dose-ranging results in May 2026; and MET-X, an antimicrobial candidate targeting multi-drug-resistant pathogens that has been exclusively licensed to Venus Remedies Ltd for the Indian market. A joint £1 million PACE grant with Justus-Liebig-University Giessen (February 2025) supports an additional first-in-class antimicrobial programme, and a Memorandum of Understanding with the Asian clinical trials network ADVANCE-ID (May 2025) extends clinical development activity into Asia.

The business model is asset-light and partnership-driven: the company does not commercialise directly but instead out-licences regional or programme rights to pharmaceutical partners (e.g., Venus Remedies in India) and supplements R&D funding through grant programmes (e.g., PACE) and equity investment, including a £4.3 million round led by Jon Moulton announced May 2026. Customer segments therefore comprise healthcare providers and health systems treating drug-resistant infections (downstream) and pharmaceutical partners/government health agencies (upstream counterparties), with revenue mechanics expected to combine upfront payments, development milestones, and royalties on eventual commercialisation.

Short descriptiontext

Infex Therapeutics is a UK-based clinical-stage biopharmaceutical company developing first-in-class anti-infective and anti-virulence drugs, including RESP-X and MET-X, to treat drug-resistant and pandemic infections, out-licensing regional rights to pharmaceutical partners such as Venus Remedies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersAlderley Edge, United Kingdom
HQ citystring
Alderley Edge
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
anti-infective therapeutics, antimicrobial drug development, anti-virulence drug research, antibiotic resistance pipeline, biopharmaceutical licensing
Industry3 codes
PRIMARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAALAC
Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels)
SECONDARYHLALAIAL
Infectious Disease & STI Testing-to-Treatment with eRx + Pharmacy Fulfillment
Healthcare & Life Sciences/Telehealth Platforms/Pharmacy-Integrated Telehealth & ePrescribing Platforms
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code3 codes
  • Pharmaceutical Preparations2834
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Medical Laboratories8071
Product category
Anti-infective Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Drug Licensing and Commercialization
TypeLicensing Royalties
Description

Infex Therapeutics acquires, develops, and licenses innovative drugs to treat pandemic infections. The company generates revenue through licensing agreements with pharmaceutical partners for development and commercialization rights to their drug candidates.

infextx.com
2Research Grants
TypeProfessional Services
Description

The company receives grant funding for specific research programs, such as the £1 million PACE grant awarded in collaboration with Justus-Liebig-University Giessen for developing first-in-class antimicrobial drugs targeting multi-drug-resistant pathogens.

infextx.com
3Equity Investment
TypeSubscription Recurring
Description

Investment from venture capital and investors such as Jon Moulton to support progression of clinical and preclinical programmes addressing critical-priority pathogens.

infextx.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

AMR Centre (operating through Infex Therapeutics) is a biopharmaceutical R&D organization that acquires, develops, and licenses innovative anti-infective drug candidates to address antimicrobial resistance and pandemic infections. The company advances a portfolio of anti-virulence and antimicrobial therapeutics — including RESP-X (INFEX702) for non-cystic fibrosis bronchiectasis and MET-X for multi-drug-resistant pathogens — through clinical development and partnership with global pharmaceutical companies for commercialization.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Positive Phase IIa dose-ranging study results for RESP-X in non-cystic fibrosis bronchiectasis patients colonised with Pseudomonas aeruginosa
Product overview1 text field

Infex Therapeutics is a biotech company developing a portfolio of innovative anti-infective drugs to treat pandemic infections and antimicrobial-resistant pathogens. The company's pipeline includes RESP-X (INFEX702), a first-in-class anti-virulence therapy in Phase IIa trials for non-cystic fibrosis bronchiectasis, and MET-X, an antimicrobial candidate targeting multi-drug-resistant infections licensed to Venus Remedies for India. The company operates from Alderley Park and collaborates with academic institutions and clinical networks globally to advance its drug candidates through clinical development.

Product and service2 records
1RESP-X (INFEX702)
CategoryAnti-virulence therapeutic — drug candidate
Description

First-in-class anti-virulence antibody drug candidate in clinical development for the treatment of non-cystic fibrosis bronchiectasis (NCFB) patients colonised with Pseudomonas aeruginosa. Aims to reduce the frequency of exacerbations by targeting bacterial virulence factors rather than killing bacteria directly, positioning the product for license to pharmaceutical partners for global commercialization.

2MET-X
CategoryAntimicrobial therapeutic — drug candidate
Description

Antimicrobial drug candidate targeting multi-drug-resistant pathogens, being advanced through clinical development under an exclusive license agreement with Venus Remedies Ltd for the Indian market. Developed as part of AMR Centre's anti-infective portfolio addressing critical-priority pathogens.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-05-21
Description

Memorandum of Understanding signed to investigate hospital-acquired drug-resistant infections. This collaboration supports the company's expansion into Asian markets for clinical development of anti-infective therapeutics.

2Venus Remedies Ltd
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-02-25
Description

Exclusive license agreement signed to advance MET-X through clinical development and commercialisation in India. Venus Remedies Ltd gains rights to develop and commercialize the antimicrobial drug candidate in the Indian market.

infextx.com
3Justus-Liebig-University Giessen
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-02-17
Description

Awarded £1 million grant from PACE to develop first-in-class antimicrobial drug targeting multi-drug-resistant pathogens. Joint research collaboration combining academic expertise with pharmaceutical development capabilities.

infextx.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Antabio is a French clinical-stage anti-infectives biotech developing novel treatments for drug-resistant bacterial infections and AMR — directly comparable to Infex's focus on first-in-class antimicrobial candidates.

TypeDirect peer
Description

Entasis (acquired by Innoviva) developed targeted anti-infective therapies for drug-resistant infections including hospital-acquired pathogens — closely aligned with Infex's AMR pipeline strategy.

TypeDirect peer
Description

BioVersys is a Swiss clinical-stage biotech developing small-molecule anti-infectives targeting AMR — comparable to Infex's therapeutic anti-infective approach and pipeline stage.

TypeDirect peer
Description

Iterum is a US-listed anti-infectives biotech developing antibiotics against multi-drug-resistant pathogens — similar therapeutic focus and clinical-stage profile to Infex.

TypeDirect peer
Description

Melinta (now a Markforged-owned antibiotics business) developed and commercialised antibiotics for drug-resistant infections — a comparable anti-infectives specialist, illustrating both the opportunity and the historic commercial challenges in the space.

TypeDirect peer
Description

VenatoRx is a US-based clinical-stage anti-infectives developer with programmes targeting resistant Gram-negative bacteria — directly comparable therapeutic area and pipeline stage.

7Nabriva Therapeutics
TypeDirect peer
Description

Nabriva is a clinical-stage anti-infectives company developing antibiotics for resistant pathogens — directly comparable to Infex's anti-infectives pipeline focus.

TypeDirect peer
Description

Tetraphase developed tetracycline-derived antibiotics for serious and drug-resistant infections before being acquired by La Jolla Pharmaceutical — a relevant historical peer demonstrating both the value creation and the commercial fragility of the anti-infectives space.

TypeDirect peer
Description

Cidara develops antiviral and anti-infective therapeutics, including immunotherapies against infectious diseases — overlaps with Infex's infectious-disease therapeutic focus, though Cidara also has an antifungal platform.

TypeOthers
Description

Achaogen was a US anti-infectives biotech that brought plazomicin to market but ultimately filed for bankruptcy due to weak antibiotic commercial economics — a cautionary historical peer highlighting commercial risks for Infex.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

AMR Centre

Anti-infective Therapeuticsamrcentre.com

Infex Therapeutics is a UK-based clinical-stage biopharmaceutical company developing first-in-class anti-infective and anti-virulence drugs, including RESP-X and MET-X, to treat drug-resistant and pandemic infections, out-licensing regional rights to pharmaceutical partners such as Venus Remedies.

What AMR Centre does

Infex Therapeutics Ltd (also known as InfexTx, and previously associated with the AMR Centre brand founded in 2016) is a UK-based clinical-stage biopharmaceutical company headquartered at Alderley Park in the North West of England. The company acquires, develops, and licences innovative drugs targeting pandemic infections and antimicrobial-resistant pathogens, with a particular emphasis on first-in-class anti-virulence therapeutics — drugs designed to neutralise bacterial virulence factors rather than kill bacteria directly, in order to reduce selective pressure for resistance. Headcount is in the 11–50 range and the company is privately held.

The pipeline centres on two named candidates: RESP-X (INFEX702), a first-in-class anti-virulence antibody drug in development for non-cystic fibrosis bronchiectasis patients colonised with Pseudomonas aeruginosa, which reported positive Phase IIa dose-ranging results in May 2026; and MET-X, an antimicrobial candidate targeting multi-drug-resistant pathogens that has been exclusively licensed to Venus Remedies Ltd for the Indian market. A joint £1 million PACE grant with Justus-Liebig-University Giessen (February 2025) supports an additional first-in-class antimicrobial programme, and a Memorandum of Understanding with the Asian clinical trials network ADVANCE-ID (May 2025) extends clinical development activity into Asia.

The business model is asset-light and partnership-driven: the company does not commercialise directly but instead out-licences regional or programme rights to pharmaceutical partners (e.g., Venus Remedies in India) and supplements R&D funding through grant programmes (e.g., PACE) and equity investment, including a £4.3 million round led by Jon Moulton announced May 2026. Customer segments therefore comprise healthcare providers and health systems treating drug-resistant infections (downstream) and pharmaceutical partners/government health agencies (upstream counterparties), with revenue mechanics expected to combine upfront payments, development milestones, and royalties on eventual commercialisation.

AMR Centre firmographics

Firmographics
Name
AMR Centre
Legal name
Infex Therapeutics Ltd.
Website
https://amrcentre.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
Infex Therapeutics is a UK-based clinical-stage biopharmaceutical company developing first-in-class anti-infective and anti-virulence drugs, including RESP-X and MET-X, to treat drug-resistant and pandemic infections, out-licensing regional rights to pharmaceutical partners such as Venus Remedies.
Ownership category
akta.pro rank

AMR Centre industry classification

Industry
Product category
Anti-infective Therapeutics
NAICS
Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714), In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAALAC
Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels)
SECONDARYHLALAIAL
Infectious Disease & STI Testing-to-Treatment with eRx + Pharmacy Fulfillment
Healthcare & Life Sciences/Telehealth Platforms/Pharmacy-Integrated Telehealth & ePrescribing Platforms

Keywords

  • Anti-infective therapeutics
  • Antimicrobial drug development
  • Anti-virulence drug research
  • Antibiotic resistance pipeline
  • Biopharmaceutical licensing

Where AMR Centre is headquartered

Location

Headquarters

HQ city
Alderley Edge
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

AMR Centre business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Drug Licensing and Commercialization: Infex Therapeutics acquires, develops, and licenses innovative drugs to treat pandemic infections. The company generates revenue through licensing agreements with pharmaceutical partners for development and commercialization rights to their drug candidates.
  2. Research Grants: The company receives grant funding for specific research programs, such as the £1 million PACE grant awarded in collaboration with Justus-Liebig-University Giessen for developing first-in-class antimicrobial drugs targeting multi-drug-resistant pathogens.
  3. Equity Investment: Investment from venture capital and investors such as Jon Moulton to support progression of clinical and preclinical programmes addressing critical-priority pathogens.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

AMR Centre product offering

Product offering

Core offering

AMR Centre (operating through Infex Therapeutics) is a biopharmaceutical R&D organization that acquires, develops, and licenses innovative anti-infective drug candidates to address antimicrobial resistance and pandemic infections. The company advances a portfolio of anti-virulence and antimicrobial therapeutics — including RESP-X (INFEX702) for non-cystic fibrosis bronchiectasis and MET-X for multi-drug-resistant pathogens — through clinical development and partnership with global pharmaceutical companies for commercialization.

Product overview

Infex Therapeutics is a biotech company developing a portfolio of innovative anti-infective drugs to treat pandemic infections and antimicrobial-resistant pathogens. The company's pipeline includes RESP-X (INFEX702), a first-in-class anti-virulence therapy in Phase IIa trials for non-cystic fibrosis bronchiectasis, and MET-X, an antimicrobial candidate targeting multi-drug-resistant infections licensed to Venus Remedies for India. The company operates from Alderley Park and collaborates with academic institutions and clinical networks globally to advance its drug candidates through clinical development.

Differentiator

Problem solved

Functional benefit

Products and services

  • RESP-X (INFEX702) First-in-class anti-virulence antibody drug candidate in clinical development for the treatment of non-cystic fibrosis bronchiectasis (NCFB) patients colonised with Pseudomonas aeruginosa. Aims to reduce the frequency of exacerbations by targeting bacterial virulence factors rather than killing bacteria directly, positioning the product for license to pharmaceutical partners for global commercialization.
  • MET-X Antimicrobial drug candidate targeting multi-drug-resistant pathogens, being advanced through clinical development under an exclusive license agreement with Venus Remedies Ltd for the Indian market. Developed as part of AMR Centre's anti-infective portfolio addressing critical-priority pathogens.

Quantifiable outcome

  • Positive Phase IIa dose-ranging study results for RESP-X in non-cystic fibrosis bronchiectasis patients colonised with Pseudomonas aeruginosa

Companies that use AMR Centre

Customer profile

Segments2 records

Ideal customer profiles3 records

AMR Centre technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

AMR Centre partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • ADVANCE-ID (Asian Clinical Trials Network)coreStrategic or Co-development Partner · 21 May 2025Memorandum of Understanding signed to investigate hospital-acquired drug-resistant infections. This collaboration supports the company's expansion into Asian markets for clinical development of anti-infective therapeutics.
  • Venus Remedies LtdcoreOEM/ Whitelabel/ Licensing Partner · 25 February 2025Exclusive license agreement signed to advance MET-X through clinical development and commercialisation in India. Venus Remedies Ltd gains rights to develop and commercialize the antimicrobial drug candidate in the Indian market.
  • Justus-Liebig-University GiessencoreStrategic or Co-development Partner · 17 February 2025Awarded £1 million grant from PACE to develop first-in-class antimicrobial drug targeting multi-drug-resistant pathogens. Joint research collaboration combining academic expertise with pharmaceutical development capabilities.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

AMR Centre competitors and assessment

Company assessment

Direct peers

  • Antabio: Antabio is a French clinical-stage anti-infectives biotech developing novel treatments for drug-resistant bacterial infections and AMR — directly comparable to Infex's focus on first-in-class antimicrobial candidates.
  • Entasis Therapeutics: Entasis (acquired by Innoviva) developed targeted anti-infective therapies for drug-resistant infections including hospital-acquired pathogens — closely aligned with Infex's AMR pipeline strategy.
  • BioVersys: BioVersys is a Swiss clinical-stage biotech developing small-molecule anti-infectives targeting AMR — comparable to Infex's therapeutic anti-infective approach and pipeline stage.
  • Iterum Therapeutics: Iterum is a US-listed anti-infectives biotech developing antibiotics against multi-drug-resistant pathogens — similar therapeutic focus and clinical-stage profile to Infex.
  • Melinta Therapeutics: Melinta (now a Markforged-owned antibiotics business) developed and commercialised antibiotics for drug-resistant infections — a comparable anti-infectives specialist, illustrating both the opportunity and the historic commercial challenges in the space.
  • VenatoRx Pharmaceuticals: VenatoRx is a US-based clinical-stage anti-infectives developer with programmes targeting resistant Gram-negative bacteria — directly comparable therapeutic area and pipeline stage.
  • Nabriva Therapeutics: Nabriva is a clinical-stage anti-infectives company developing antibiotics for resistant pathogens — directly comparable to Infex's anti-infectives pipeline focus.
  • Tetraphase Biosciences: Tetraphase developed tetracycline-derived antibiotics for serious and drug-resistant infections before being acquired by La Jolla Pharmaceutical — a relevant historical peer demonstrating both the value creation and the commercial fragility of the anti-infectives space.
  • Cidara Therapeutics: Cidara develops antiviral and anti-infective therapeutics, including immunotherapies against infectious diseases — overlaps with Infex's infectious-disease therapeutic focus, though Cidara also has an antifungal platform.

Others

  • Achaogen: Achaogen was a US anti-infectives biotech that brought plazomicin to market but ultimately filed for bankruptcy due to weak antibiotic commercial economics — a cautionary historical peer highlighting commercial risks for Infex.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

AMR Centre social profiles

Digital presence

AMR Centre financial estimates

Financial estimate

Revenue estimate

Valuation estimate

AMR Centre leadership team

Management profile

Number of profiles

Profiles5 records

AMR Centre funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

AMR Centre M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AMR Centre

What does AMR Centre do?

AMR Centre (operating through Infex Therapeutics) is a biopharmaceutical R&D organization that acquires, develops, and licenses innovative anti-infective drug candidates to address antimicrobial resistance and pandemic infections. The company advances a portfolio of anti-virulence and antimicrobial therapeutics — including RESP-X (INFEX702) for non-cystic fibrosis bronchiectasis and MET-X for multi-drug-resistant pathogens — through clinical development and partnership with global pharmaceutical companies for commercialization.

Is AMR Centre a public or private company?

AMR Centre is a private company. It is classified as venture growth investor backed and is currently operating.

When was AMR Centre founded?

AMR Centre was founded in 2016. It employs 11 to 50 people.

Where is AMR Centre based?

AMR Centre is headquartered in Alderley Edge, United Kingdom, in the Europe region.

How does AMR Centre make money?

Three revenue lines are on record. Drug Licensing and Commercialization is the primary driver. The others are research Grants and equity Investment.

Who are AMR Centre's main competitors?

Direct peers on record are Antabio, Entasis Therapeutics, BioVersys, Iterum Therapeutics, Melinta Therapeutics, VenatoRx Pharmaceuticals, Nabriva Therapeutics, Tetraphase Biosciences and Cidara Therapeutics. Achaogen is listed as an others.

Does AMR Centre have an API?

No public API is recorded for AMR Centre.

What industry is AMR Centre in?

AMR Centre's product category is Anti-infective Therapeutics. Its primary akta.pro industry code is HLAIAAAG, Infectious Disease & Antimicrobials Pharmaceuticals, with a secondary code of HLAAALAC, Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BusinessCloudAMR Centre agrees exciting deal with US biotech firmThe AMR Centre at Alderley Park signed a co-development agreement with US biotech Microbiotix to accelerate development of a bacterial virulence drug candidate. The partnership includes up to $1.1m in technical support and over $600,000 in project funding, building on a $3.2m CARB-X award.PR NewswireMicrobiotix and the AMR Centre Announce Co-Development Agreement Targeting Drug Resistant P. aeruginosa in Critically Ill Pneumonia PatientsMicrobiotix, Inc. and the AMR Centre announced a co-development agreement to accelerate the development of Microbiotix's T3SS (type III secretion system) inhibitor project targeting drug-resistant P. aeruginosa in critically ill pneumonia patients. The AMR Centre will provide up to $1.1 million in technical support and project funding, combining with $1.6 million in initial CARB-X funding, to identify a drug candidate for clinical trials. The novel T3SS inhibitors address the infection's effects without directly killing the organism, potentially avoiding the development of antibiotic resistance.PR NewswireInternational Partnership Established to Tackle Antimicrobial ResistanceThe U.S. Department of Health and Human Services, the Wellcome Trust, the AMR Centre, and Boston University School of Law announced the establishment of CARB-X, one of the world's largest public-private partnerships focused on tackling antibiotic resistance, on July 28, 2016. BARDA will provide up to $250 million over five years and the AMR Centre up to $100 million over five years to accelerate development of new antibiotics, diagnostics, and vaccines. The initiative responds to economist Jim O'Neill's May 2016 report calling for coordinated global action to address the growing public health threat of antimicrobial resistance.